ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
ImmunityBio has raised $80.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.
ImmunityBio's investors include Oberland Capital, Patrick Soon-Shiong, NantCapital.
ImmunityBio is headquartered in Culver City, United States.
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
ImmunityBio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmunityBio — Funding & Investors." VCBacked, July 25, 2025, https://www.vcbacked.co/company/immunitybio. Accessed August 14, 2026.
VCBacked. (2025). ImmunityBio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immunitybio
{{cite web |title=ImmunityBio — Funding & Investors |url=https://www.vcbacked.co/company/immunitybio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated